Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to -$2.7 billion.

  • Iovance Biotherapeutics' Retained Earnings changed N/A to -$2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 billion, marking a year-over-year change of. This contributed to the annual value of -$2.4 billion for FY2024, which is 1849.44% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Retained Earnings of -$2.7 billion as of Q3 2025.
  • Iovance Biotherapeutics' Retained Earnings' 5-year high stood at -$1.7 billion during Q1 2023, with a 5-year trough of -$2.7 billion in Q3 2025.
  • For the 3-year period, Iovance Biotherapeutics' Retained Earnings averaged around -$2.2 billion, with its median value being -$2.1 billion (2024).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Retained Earnings plummeted by 2683.3% in 2024, and later tumbled by 1766.13% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Retained Earnings stood at -$2.0 billion in 2023, then decreased by 18.49% to -$2.4 billion in 2024, then fell by 13.38% to -$2.7 billion in 2025.
  • Its Retained Earnings was -$2.7 billion in Q3 2025, compared to -$2.6 billion in Q2 2025 and -$2.5 billion in Q1 2025.